healthgevity bpc-157 BPC+PEA 500 – BPC+KPV+PEA 500 – Healthgevity

Serious adverse events are extremely rare, with most subjects tolerating the peptide well throughout research protocols

[DOI] [PubMed] [Google Scholar] 157.Erickson JC, Hollopeter G, Palmiter RD

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin

L.RossiJ

(8) The researchers also commented that introduction of the peptide appeared to have increased bone mineralization in the murine models subjected to a combination of Ipamorelin and catabolism-inducing agents, in contrast to the control group receiving only catabolism-inducing agents